HPV-positive HNSCC cell lines but not primary human fibroblasts are radiosensitized by the inhibition of Chk1

Radiotherapy and Oncology

Volumn 108, Issue 3, 2013, Pages 495-499

  Busch, Chia Jung ^a   Kriegs, Malte ^a   Laban, Simon ^a   Tribius, Silke ^a   Knecht, Rainald ^a   Petersen, Cordula ^a   Dikomey, Ekkehard ^a   Rieckmann, Thorsten ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Chk1; G2 arrest; HNSCC; HPV; p16; Radiosensitivity

Indexed keywords

CHECKPOINT KINASE 1; PROTEIN P16;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE DISTRIBUTION; CELL CYCLE PARAMETERS; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; FIBROBLAST; FIBROBLAST CULTURE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INHIBITION KINETICS; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; WART VIRUS; WESTERN BLOTTING;

CHK1; G2-ARREST; HNSCC; HPV; P16; RADIOSENSITIVITY;

CARCINOMA, SQUAMOUS CELL; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; FIBROBLASTS; G2 PHASE; HEAD AND NECK NEOPLASMS; HUMANS; PAPILLOMAVIRIDAE; PHOSPHORYLATION; PROTEIN KINASES; RADIATION TOLERANCE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84887017554     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.06.035     Document Type: Article

References (16)

1. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
2. K.K. Ang, and E.M. Sturgis Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma Semin Radiat Oncol 22 2012 128 142
3. C.A. Moody, and L.A. Laimins Human papillomavirus oncoproteins: pathways to transformation Nat Rev Cancer 10 2010 550 560
4. T. Rieckmann, S. Tribius, and T.J. Grob HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity Radiother Oncol 107 2013 242 246
5. K. Kuntz, and M.J. O'Connell The G(2) DNA damage checkpoint: could this ancient regulator be the Achilles heel of cancer? Cancer Biol Ther 8 2009 1433 1439
6. Y. Dai, and S. Grant New insights into checkpoint kinase 1 in the DNA damage response signaling network Clin Cancer Res 16 2010 376 383
7. A. Blasina, J. Hallin, and E. Chen Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1 Mol Cancer Ther 7 2008 2394 2404
8. P.T. Ferrao, E.P. Bukczynska, R.W. Johnstone, and G.A. McArthur Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells Oncogene 31 2012 1661 1672
9. W. Eicheler, D. Zips, A. Dorfler, R. Grenman, and M. Baumann Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection J Histochem Cytochem 50 2002 197 204
10. N. Magne, J.L. Fischel, and A. Dubreuil ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine Clin Cancer Res 9 2003 4735 4742
11. K.J. Russell, L.W. Wiens, G.W. Demers, D.A. Galloway, S.E. Plon, and M. Groudine Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells Cancer Res 55 1995 1639 1642
12. Q. Wang, S. Fan, A. Eastman, P.J. Worland, E.A. Sausville, and P.M. O'Connor UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53 J Natl Cancer Inst 88 1996 956 965
13. J.B. Mitchell, R. Choudhuri, and K. Fabre In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762 Clin Cancer Res 16 2010 2076 2084
14. G.R. Borst, M. McLaughlin, and J.N. Kyula Targeted radiosensitization by the Chk1 inhibitor SAR-020106 Int J Radiat Oncol Biol Phys 85 2013 1110 1118
15. C. Zhang, Z. Yan, and C.L. Painter PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts Clin Cancer Res 15 2009 4630 4640
16. N. Brega, G.A. McArthur, C. Britten, S.G. Wong, E. Wang, and K.D. Wilner Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase J Clin Oncol 2010 28 (Meeting Abstracts) abstr 3062